{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"letrozole-palbociclib"},{"type":"Synonym","name":"palbociclib + letrozole"},{"type":"Synonym","name":"letrozole + palbociclib"},{"type":"Synonym","name":"letrozole/palbociclib"},{"type":"Synonym","name":"Femara/Ibrance"},{"type":"Synonym","name":"letrozole-palbociclib regimen"}],"definition":{"html":"A regimen consisting of letrozole and palbociclib that can be used in the treatment of breast cancer.","text":"A regimen consisting of letrozole and palbociclib that can be used in the treatment of breast cancer."},"drugInfoSummaryLink":null,"nciConceptId":"C142859","nciConceptName":"Letrozole/Palbociclib Regimen","termId":791794,"name":"letrozole/palbociclib regimen","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"letrozole-palbociclib-regimen"},{"aliases":[{"type":"CodeName","name":"PD-0332991"},{"type":"CASRegistryName","name":"571190-30-2"},{"type":"CodeName","name":"PD-332991"},{"type":"ChemicalStructureName","name":"6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one"},{"type":"USBrandName","name":"Ibrance"},{"type":"Synonym","name":"6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one"},{"type":"CodeName","name":"PD 0332991"},{"type":"CodeName","name":"PD 332991"},{"type":"CodeName","name":"PD 991"},{"type":"ChemicalStructureName","name":"Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-"}],"definition":{"html":"An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","text":"An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/palbociclib","text":"Palbociclib"},"nciConceptId":"C49176","nciConceptName":"Palbociclib","termId":454586,"name":"Palbociclib","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"palbociclib"}],"links":null}